Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ALKEM.BO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ALKEM.BO and 80,000+ other tickers.
See exactly how ALKEM.BO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ALKEM.BO and 80,000+ other tickers.
Operating as a pharmaceutical firm, Alkem Laboratories Limited is actively engaged in the research, manufacturing, and commercialization of medicinal and nutritional products, distributed both within India and internationally. The company's diverse product range includes branded and unbranded generic medications, active pharmaceutical ingredients (APIs), biosimilars, and various nutraceuticals. These solutions cater to numerous acute and chronic health concerns, spanning anti-infective therapies, dermatology, cardiology, respiratory ailments, gastrointestinal health, central nervous system…
No recent news available.